New oral anticoagulants for the treatment of venous thromboembolism

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 2, 2013, Pages 151-161

  Agnelli, Giancarlo ^a   Becattini, Cecilia ^a   Franco, Laura ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

apixaban; dabigatran; edoxaban; oral anticoagulants; pulmonary embolism; rivaroxaban; venous thromboembolism; venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HUMAN; HYPOTENSION; KIDNEY CLEARANCE; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84882272915     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.07.005     Document Type: Review

References (35)

1. F.A. Anderson Jr., H.B. Wheeler, and R.J. Goldberg A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study Arch Intern Med 151 1991 933 938
2. Prandoni The long term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
3. J.A. Heit, D.N. Mohr, and M.D. Silverstein Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study Arch Intern Med 160 2000 761 768
4. P. Kyrle, F. Rosendal, and S. Eichinger Risk assessment for recurrent venous thrombosis Lancet 376 2010 2032 2039
5. A. Torbicki, A. Perrier, and S. Konstantinides Guidelines on the diagnosis and management of acute pulmonary embolism. The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur Heart J 29 2008 2276 2315
6. G. Agnelli, and C. Becattini Acute pulmonary embolism N Engl J Med 363 2010 266 274
7. C. Kearon, E.A. Akl, A.J. Comerota American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2 Suppl. 2012 e419S e494S
8. H.R. Buller, B.L. Davidson, and H. Decousus Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial Ann Intern Med 140 2004 867 873
9. H.R. Buller, B.L. Davidson, and H. Decousus Subcutaneous fondaparinux versus intravenous infractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 2003 1695 1702
10. P. Prandoni, F. Noventa, and A. Ghirarduzzi The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica 92 2007 199 205
11. G. Agnelli, P. Prandoni, and C. Becattini Warfarin optimal duration italian trials investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism Ann Intern Med 139 2003 19 25
12. G. Agnelli, P. Prandoni, and M.G. Santamaria Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis N Engl J Med 345 2001 165 169
13. I.A. Campbell, D.P. Bentley, and R.J. Prescott Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial BMJ 334 2007 674
14. F. Boutitie, L. Pinede, and S. Schulman Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials BMJ 342 2011 d3036
15. P. Prandoni, A.W. Lensing, and A. Piccioli Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
16. S. Schulman, S. Granqvist, and M. Holmstrom The duration of oral anticoagulant therapy after a second episode of venous thromboembolism N Engl J Med 336 1997 393 398
17. M. Di Nisio, S. Middeldorp, and H.R. Büller Direct thrombin inhibitors N Engl J Med 353 2005 1028 1040
18. B.E. Baetz, and S.A. Spinler Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases Pharmacotherapy 28 2008 1354 1373
19. D. Kubitza, M. Becka, and B. Voith Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421
20. N. Raghavan, C.E. Frost, and Z. Yu Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
21. I. Ahrens, and C. Bode Oral anticoagulation with edoxaban. Focus on current phase III clinical development Hämostaseologie 32 2012 212 215
22. A.J. Camm, and H. Bounameaux Edoxaban: a new oral direct factor Xa inhibitor Drugs 71 2011 1503 1526
23. C.B. Granger, J.H. Alexander, J.J. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
24. M.R. Patel, K.W. Mahaffey, J. Garg ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
25. S. Schulman, C. Kearon, A.K. Kakkar RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
26. S. Schulman, A.K. Kakkar, and S.M. Schellong A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) ASH Annual Meeting Abstracts Blood 118 2011 205
27. G. Agnelli, A. Gallus, and S.Z. Goldhaber Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study Circulation 116 2007 180 187
28. H.R. Buller, A.W.A. Lensing, and M.H. Prins A dose-ranging study evaluating once daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study Blood 112 2008 2242 2247
29. R. Bauersachs, S.D. Berkowitz, and B. Brenner Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
30. Einstein Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
31. Botticelli Investigators, Writing Committe H. Buller, D. Deitchman, and M. Prins Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J Thromb Haemost 2008 1313 1318
32. S. Schulman, C. Kearon, and A.K. Kakkar Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
33. G. Agnelli, H.R. Buller, and A. Cohen Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2012 699 708
34. C. Becattini, G. Agnelli, and A. Schenone Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 2012 1959 1967
35. T.A. Brighton, J.W. Eikelboom, and K. Mann Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 367 2012 1979 1987